Jonathan Rubin

400 total citations
32 papers, 257 citations indexed

About

Jonathan Rubin is a scholar working on Psychiatry and Mental health, Cognitive Neuroscience and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Jonathan Rubin has authored 32 papers receiving a total of 257 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Psychiatry and Mental health, 12 papers in Cognitive Neuroscience and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Jonathan Rubin's work include Attention Deficit Hyperactivity Disorder (28 papers), Bipolar Disorder and Treatment (9 papers) and Functional Brain Connectivity Studies (7 papers). Jonathan Rubin is often cited by papers focused on Attention Deficit Hyperactivity Disorder (28 papers), Bipolar Disorder and Treatment (9 papers) and Functional Brain Connectivity Studies (7 papers). Jonathan Rubin collaborates with scholars based in United States, United Kingdom and Israel. Jonathan Rubin's co-authors include Azmi Nasser, Joseph T. Hull, Gregory D. Busse, Ann Childress, Zare Melyan, Alisa R. Kosheleff, Carla White, Stephen V. Faraone, Roberto Goméni and Sharon Youcha and has published in prestigious journals such as Neurology, Journal of the American Academy of Child & Adolescent Psychiatry and British Journal of Anaesthesia.

In The Last Decade

Jonathan Rubin

27 papers receiving 241 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonathan Rubin United States	11	233	118	28	26	22	32	257
Tesfaye Liranso United States	9	333 1.4×	154 1.3×	45 1.6×	29 1.1×	56 2.5×	30	348
E Ramstad Denmark	5	361 1.5×	152 1.3×	83 3.0×	56 2.2×	24 1.1×	5	408
Hai Jiang China	5	200 0.9×	92 0.8×	32 1.1×	27 1.0×	18 0.8×	12	229
Valerie Arnold United States	8	185 0.8×	89 0.8×	55 2.0×	39 1.5×	17 0.8×	23	219
Marco Bottelier Netherlands	10	189 0.8×	131 1.1×	42 1.5×	26 1.0×	8 0.4×	18	250
Cynthia Kerson United States	7	115 0.5×	250 2.1×	26 0.9×	17 0.7×	6 0.3×	14	290
Justina Sidlauskaite Belgium	8	108 0.5×	195 1.7×	31 1.1×	10 0.4×	6 0.3×	12	261
Jay Gunkelman United States	8	152 0.7×	250 2.1×	22 0.8×	13 0.5×	16 0.7×	16	300
Markus Kölle Germany	9	94 0.4×	81 0.7×	53 1.9×	3 0.1×	38 1.7×	24	248
Colleen Anderson United States	11	351 1.5×	183 1.6×	66 2.4×	59 2.3×	54 2.5×	15	416

Countries citing papers authored by Jonathan Rubin

Since Specialization

Citations

This map shows the geographic impact of Jonathan Rubin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Rubin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Rubin more than expected).

Fields of papers citing papers by Jonathan Rubin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Rubin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Rubin. The network helps show where Jonathan Rubin may publish in the future.

Co-authorship network of co-authors of Jonathan Rubin

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Rubin. A scholar is included among the top collaborators of Jonathan Rubin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Rubin. Jonathan Rubin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yegla, Brittney, et al.. (2025). Apomorphine differentially engages the cAMP and β-arrestin signaling pathways relative to dopamine at human dopamine receptors. Journal of Neural Transmission. 132(11). 1751–1760.

Childress, Ann, et al.. (2025). Viloxazine Extended-Release Administered With Psychostimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Phase 4, Open-Label Trial. Journal of Child and Adolescent Psychopharmacology. 35(3). 155–166. 1 indexed citations

Solomon, Matia B., et al.. (2025). Revisiting the Role of Serotonin in Attention-Deficit Hyperactivity Disorder: New Insights from Preclinical and Clinical Studies. Clinical Drug Investigation. 45(10). 701–742.

Nasser, Azmi, Roberto Goméni, Gianpiera Ceresoli‐Borroni, et al.. (2024). Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease. Journal of Pharmacokinetics and Pharmacodynamics. 51(4). 385–393. 1 indexed citations

Childress, Ann, et al.. (2024). An Open-Label Extension Study Assessing the Long-Term Safety and Efficacy of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder. CNS Drugs. 38(11). 891–907. 1 indexed citations

García‐Olivares, Jennie, et al.. (2024). Viloxazine Increases Extracellular Concentrations of Norepinephrine, Dopamine, and Serotonin in the Rat Prefrontal Cortex at Doses Relevant for the Treatment of Attention-Deficit/Hyperactivity Disorder. Journal of Experimental Pharmacology. Volume 16. 13–24. 5 indexed citations

Mattingly, Gregory W., et al.. (2024). Efficacy of Viloxazine ER (Qelbree) for ADHD in Adults Based on Prior Stimulant Exposure. CNS Spectrums. 29(5). 490–491. 1 indexed citations

Childress, Ann, et al.. (2024). Qelbree (viloxazine extended-release capsules): Final Results of the Long-Term, Phase 3, Open-Label Extension Trial in Adults with ADHD. CNS Spectrums. 29(5). 479–480. 1 indexed citations

Nasser, Azmi, Joseph T. Hull, Jennifer Koch, et al.. (2023). Effects of Viloxazine ER (Qelbree®) on Weight and Height Trajectories: Interim Results From a Long-term, Open-Label Extension Trial in Pediatric ADHD. CNS Spectrums. 28(2). 218–218. 1 indexed citations

10.

Findling, Robert L., Jeffrey H. Newcorn, Andrew J. Cutler, et al.. (2023). 5.13 Evaluation of the Efficacy of Viloxazine ER in ADHD Inattentive and Combined Presentations. Journal of the American Academy of Child & Adolescent Psychiatry. 62(10). S262–S263.

11.

Nasser, Azmi, et al.. (2023). Evaluating the Impact of Caffeine on the Incidence of Adverse Events During Treatment with Viloxazine Extended-Release (Qelbree®) in Adults with ADHD. CNS Spectrums. 28(2). 234–235. 1 indexed citations

12.

Faraone, Stephen V., Roberto Goméni, Joseph T. Hull, et al.. (2023). Response of peer relations and social activities to treatment with viloxazine extended‐release capsules (Qelbree ^® ): A post hoc analysis of four randomized clinical trials of children and adolescents with attention‐deficit/hyperactivity disorder. Brain and Behavior. 13(4). e2910–e2910. 5 indexed citations

13.

Findling, Robert L., et al.. (2023). 2.43 Viloxazine Extended-Release Capsules in Children and Adolescents With ADHD: Final Results of a Long-Term, Phase 3, Open-Label Extension Study. Journal of the American Academy of Child & Adolescent Psychiatry. 62(10). S194–S194.

14.

Nasser, Azmi, Joseph T. Hull, Tesfaye Liranso, et al.. (2022). A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder. CNS Drugs. 36(8). 897–915. 32 indexed citations

15.

Faraone, Stephen V., Roberto Goméni, Joseph T. Hull, et al.. (2022). Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial. Psychiatry Research. 318. 114922–114922. 13 indexed citations

16.

Nasser, Azmi, Alisa R. Kosheleff, Joseph T. Hull, et al.. (2021). Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology. 31(3). 214–226. 12 indexed citations

17.

Faraone, Stephen V., Roberto Goméni, Joseph T. Hull, et al.. (2021). Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials. Psychiatry Research. 296. 113664–113664. 23 indexed citations

18.

Faraone, Stephen V., Roberto Goméni, Joseph T. Hull, et al.. (2021). Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials. Pediatric Drugs. 23(6). 583–589. 12 indexed citations

19.

Cutler, Andrew J., Matthew Brams, Oscar G. Bukstein, et al.. (2014). Response/Remission With Guanfacine Extended-Release and Psychostimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child & Adolescent Psychiatry. 53(10). 1092–1101. 19 indexed citations

20.

Ángel-González, Mario, et al.. (2009). Effects of Application to Two Different Skin Sites on the Pharmacokinetics of Transdermal Methylphenidate in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology. 19(3). 227–232. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact